QIAGEN N.V. Annual Report 2001

More documents

Recommendations

Info

later, he became Senior Vice President and head of R&D, Switzerland. In 1992, Prof. Dr. Karobath joined Rhone Poulenc Rorer (”RPR”) as President of R&D and Executive Vice President and later he became a member of the Boards of Directors of RPR, Pasteur Mérieux Connought, Centeon and Rhone Poulenc Pharma. He has received several scientific awards and has published 92 scientific papers. Dr. Karobath also serves as an executive board member of Coley Pharmaceutical Group, as chairman and executive board member of IDEA AG and as deputy chairman and executive board member of CARDION AG. 64 Professor Dr. jur. Carsten P. Claussen was Chairman of the Supervisory Board of the Company from 1988 to June 1999 and was appointed as a Special Advisor and Honorary Chairman in 1999. Professor Claussen is no longer a voting member of the Supervisory Board. For many years he has pursued a career in private banking. Between 1976 and 1987, Professor Claussen was a member of the Executive Board of Norddeutsche Landsbank, Hannover, and Chairman of the Hannover Stock Exchange. Since 1987, he has been a lawyer in Duesseldorf and senior advisor to IKB Deutsche Industriekreditbank, Düsseldorf. At present, he is a partner in the law firm of Hoffmann Liebs and Partner and specializes in corporate law and capital market transactions. He is Chairman of the Board of TON ART AG, Duesseldorf; Flossbach & v. Storch Vermögensmangagement AG, Cologne; Co.don AG, Teltow and WAS Worldwide Analytical Systems AG, Cleve and is a member of other boards. Professor Claussen received his Ph.D. in law from the University of Cologne. AUDIT AND COMPENSATION COMMITTEES The Audit Committee consists of two members, Dr. Hornef (Chairman) and Mr. Walter, and meets at least quarterly. The Audit Committee members are appointed by the Supervisory Board and serve for a term of one year. The Audit Committee recommends the selection of independent public accountants to audit the consolidated financial statements and local books and records of the Company and its subsidiaries, along with approving the fees for such services; reviews the performance of the independent public accountants with management, discusses on a quarterly basis the scope and results of the reviews and audits with the independent public accountants; discusses the Company’s financial accounting and reporting principles and policies and the adequacy of the Company’s internal accounting, financial and operating controls with the independent public accountants and management; considers and approves any recommendations regarding changes to the Company’s accounting policies and processes; reviews with management and the independent public accountants the Company’s quarterly earnings reports prior to its release to the press; and reviews the quarterly and annual reports (reported on Forms 6-K and 20-F) to be filed with the Securities Exchange Commission and the Deutsche Börse. The Compensation Committee consists of two members: Professor Riesner (Chairman) and Dr. Wirtz. Members are appointed by the Supervisory Board and serve for a term of one year. The Compensation Committee reviews and approves all stock option grants, reviews and approves the annual salaries, bonuses and other benefits of executive officers, and reviews general policies relating to employee compensation and benefits. MARKET INFORMATION The Company approved a four-for-one stock split during fiscal 2000 and a two-for-one stock split and par value currency conversion in fiscal 1999. To effect the four-for-one stock split, on June 16, 2000, the shareholders of the Company approved the amendment of the Company’s Articles of Association to increase the number of authorized shares of common stock from 65 million to 260 million. The Company’s Board of Supervisory Directors and Managing Board approved the split in May 2000. Common shareholders of record on July 3, 2000 received three additional shares for each share held on that date. The additional shares were distributed and the stock split was effective on July 13, 2000. On June 18, 1999, the shareholders of the Company approved the amendment of the Company’s Articles of Association to increase the number of authorized shares of common stock from 32.5 million to 65 million, which was required to effect the two-for-one stock split that the Company’s Board of Supervisory Directors and Managing Board approved in May 1999. Common shareholders of record on July 2, 1999 received one additional share for each share held on that date. The additional shares were distributed and the stock split was effective on July 16, 1999.
Since June 27, 1996, the Common Shares have been quoted on the NASDAQ National Market under the symbol QGENF. The following table sets forth the annual high and low closing sale prices for the last five years, the quarterly high and low closing sale prices for the last two fiscal years, and the monthly high and low closing sale prices for the last six months of the Common Shares on the NASDAQ National Market. All share prices prior to July 13, 2000 have been restated to reflect the stock splits. Annual High ($) Low ($) 1997 7.375 3.031 1998 9.500 5.234 1999 20.875 8.188 2000 57.375 18.813 2001 35.375 12.380 Quarterly 2000: High ($) Low ($) First Quarter 55.500 18.813 Second Quarter 48.938 29.250 Third Quarter 57.375 44.000 Fourth Quarter 45.938 29.500 65 Quarterly 2001: High ($) Low ($) First Quarter 35.375 18.375 Second Quarter 28.000 18.480 Third Quarter 23.330 12.380 Fourth Quarter 20.690 14.900 2002: First Quarter (through March 15, 2002) 20.81 14.000 Monthly: High ($) Low ($) September 2001 20.530 12.380 October 2001 18.500 14.900 November 2001 20.690 17.150 December 2001 20.140 18.330 January 2002 20.810 18.700 February 2002 19.780 15.300
Page 1 and 2:
QIAGEN N.V. Annual Report 2001 QIAG
Page 3 and 4:
Financial Highlights Financial High
Page 5 and 6:
Report of the Supervisory Board Eri
Page 7 and 8:
Letter from the Managing Board To O
Page 9 and 10:
QIAGEN — Focusing the Power of Li
Page 11 and 12:
QIAGEN — Focusing the Power of Li
Page 13 and 14:
— Cellomics QIAGEN — Focusing t
Page 15 and 16: QIAGEN — Focusing the Power of Li
Page 17 and 18: QIAGEN — Focusing the Power of Li
Page 19 and 20: SELECTED CONSOLIDATED FINANCIAL DAT
Page 21 and 22: RESULTS OF OPERATIONS The following
Page 23 and 24: Operon, and QIAGEN Sciences, Inc. (
Page 25 and 26: as a result, operating costs relate
Page 27 and 28: credit lines totaling $9.6 million
Page 29 and 30: $360,000, based on the year-end int
Page 31 and 32: QIAGEN N.V. AND SUBSIDIARIES CONSOL
Page 39 and 40: in affiliated companies that are 50
Page 41 and 42: n. Financial Instruments In the ord
Page 43 and 44: December 31, 2001 (January 1, 2001
Page 45 and 46: During 1997, the Company purchased
Page 47 and 48: On March 20, 1997, the Company sold
Page 49 and 50: As of December 31, 2001 and 2000, t
Page 51 and 52: Long-term debt consists of the foll
Page 53 and 54: The Company has elected to adopt SF
Page 55 and 56: 17. LICENSING AGREEMENTS The Compan
Page 57 and 58: Assets Germany United States Switze
Page 59 and 60: STATEMENTS OF INCOME FOR THE YEAR E
Page 61 and 62: 7. SHAREHOLDERS’ EQUITY The autho
Page 63 and 64: OTHER INFORMATION 2. STATUTORY PROF
Page 65: 1977, Lecturer of Biophysical Chemi
Page 69 and 70: Corporate Headquarters QIAGEN N.V.
Page 71: QIAGEN Investor Relations Dr. Solve
show all

QIAGEN N.V. Annual Report 2001

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?